|
1
|
Ghaneh P, Costello E and Neoptolemos JP:
Biology and management of pancreatic cancer. Gut. 56:1134–1152.
2007.PubMed/NCBI
|
|
2
|
Zhang Y and Shi X: Progress in the
chemotherapy of pancreatic carcinoma. World Chin J Digestology.
17:1422–1426. 2009.
|
|
3
|
Suganuma M, Okabe S, Sueoka N, Sueoka E,
Matsuyama S, Imai K, Nakachi K and Fujiki H: Green tea and cancer
chemo-prevention. Mutat Res. 428:339–344. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shankar S, Ganapathy S and Srivastava RK:
Green tea poly-phenols: Biology and therapeutic implications in
cancer. Front Biosci. 12:4881–4899. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang CS, Ju J, Lu G, Xiao H, Hao X, Sang S
and Lambert JD: Cancer prevention by tea and tea polyphenols. Asia
Pac J Clin Nutr. 17(Suppl 1): S245–S248. 2008.
|
|
6
|
Hastak K, Gupta S, Ahmad N, Agarwal MK,
Agarwal ML and Mukhtar H: Role of P53 and NF-kappaB
inepigal-locatechin3-gallate-induced apoptosis of LNCaP cells.
Oncogene. 22:4851–4859. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maeda-Yamamoto M, Suzuki N, Sawai Y,
Miyase T, Sano M, Hashimoto-Ohta A and Isemura M: Association of
suppression of extracellular signal-regulated kinase
phosphorylation by epigallocatechin gallate with the reduction of
matrix metalloproteinase activities in human fibrosarcoma HT1080
cells. J Agic Food Chem. 51:1858–1863. 2003. View Article : Google Scholar
|
|
8
|
Roy M, Chakrabarty S, Sinha D,
Bhattacharya RK and Siddiqi M: Anticlastogenic, antigenotoxic and
apoptoic antivity of epigallocatechin gallate: A green tea
polyphenol. Mutat Res. 523–524:33–41. 2003. View Article : Google Scholar
|
|
9
|
Mittal A, Pate MS, Wylie RC, Tollefsbol TO
and Katiyar SK: EGCG downregulates telomerase in human breast
carcinoma MCF-7 cells, leading to suppression of cell viability and
induction of apotosis. Int J Oncol. 24:703–710. 2004.PubMed/NCBI
|
|
10
|
Mukhtar H and Ahmad N: Tea polyphenols:
Prevention of cancer and optimizing health. Am J Clin Nutr.
71(Suppl 6): S1698–S1702; discussion S1703–S1704. 2000.
|
|
11
|
Lambert JD and Yang CS: Cancer
chemopreventive activity and bioavailability of tea and tea
polyphenols. Mutat Res. 523–524:201–208. 2003. View Article : Google Scholar
|
|
12
|
Bode AM and Dong Z: Targeting signal
transduction pathways by chemopreventive agents. Mutat Res.
555:33–51. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang CS, Chung JY, Yang G, Chhabra SK and
Lee MJ: Tea and tea polyphenols in cancer prevention. J Nutr.
130(2S Suppl): S472–S478. 2000.
|
|
14
|
Leone M, Zhai D, Sareth S, Kitada S, Reed
JC and Pellecchia M: Cancer prevention by tea polyphenols is linked
to their direct inhibition of antiapoptotic Bcl-2-family proteins.
Cancer Res. 63:8118–8121. 2003.PubMed/NCBI
|
|
15
|
Pellecchia M and Reed JC: Inhibition of
anti-apoptotic Bcl-2 family proteins by natural polyphenols: New
avenues for cancer chemoprevention and chemotherapy. Curr Pharm
Des. 10:1387–1398. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang CS, Lambert JD, Hou Z, Ju J, Lu G and
Hao X: Molecular targets for the cancer preventive activity of tea
polyphenols. Mol Carcinog. 45:431–435. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Surh YJ: Cancer chemoprevention with
dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanwar J, Taskeen M, Mohammad I, Huo C,
Chan TH and Dou QP: Recent advances on tea polyphenols. Front
Biosci (Elite Ed). 4:111–131. 2012. View
Article : Google Scholar
|
|
19
|
Morgan TM, Koreckij TD and Corey E:
Targeted therapy for advanced prostate cancer: Inhibition of the
PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 9:237–249. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Downward J: PI3-kinase, Akt and cell
survival. Semin Cell Dev Biol. 15:177–182. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu G, Zhang W, Bertram P, Zheng XF and
McLeod H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR
pathway in common human tumors. Int J Oncol. 24:893–900.
2004.PubMed/NCBI
|
|
22
|
Liu S, Wang XJ, Liu Y and Cui YF:
PI3K/AKT/mTOR signaling is involved in
(−)-epigallocatechin-3-gallate-induced apoptosis of human
pancreatic carcinoma cells. Am J Chin Med. 41:629–642. 2013.
View Article : Google Scholar
|
|
23
|
Lin CF, Young KC, Bai CH, Yu BC, Ma CT,
Chien YC, Chiang CL, Liao CS, Lai HW and Tsao CW: Rosiglitazone
regulates anti-inflammation and growth inhibition via PTEN. Biomed
Res Int. 2014:7879242014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie F, Su M, Qiu W, Zhang M, Guo Z, Su B,
Liu J, Li X and Zhou L: Kaempferol promotes apoptosis in human
bladder cancer cells by inducing the tumor suppressor, PTEN. Int J
Mol Sci. 14:21215–21226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Zhang J, Xu K, Xiao Z, Sun J, Xu
J, Wang J and Tang Q: PTEN/PI3K/mTOR/B7-H1 signaling pathway
regulates cell progression and immuno-resistance in pancreatic
cancer. Hepatogastroenterology. 60:1766–1772. 2013.
|
|
26
|
Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A,
Takahashi H, Wakasugi T, Funahashi H, Sato M and Takeyama H: IGF-1
mediates PTEN suppression and enhances cell invasion and
proliferation via activation of the IGF-1/PI3K/Akt signaling
pathway in pancreatic cancer cells. J Surg Res. 160:90–101. 2010.
View Article : Google Scholar
|
|
27
|
Lyn-Cook BD, Rogers T, Yan Y, Blann EB,
Kadlubar FF and Hammons GJ: Chemopreventive effects of tea extracts
and various components on human pancreatic and prostate tumor cells
in vitro. Nutr Cancer. 35:80–86. 1999. View Article : Google Scholar
|
|
28
|
Qanungo S, Das M, Haldar S and Basu A:
Epigallocatechin-3-gallate induces mitochondrial membrane
depolarization and caspase-dependent apoptosis in pancreatic cancer
cells. Carcinogenesis. 26:958–967. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang LY, Li X and Han YZ: Neuroprotection
by epigallocatechin gallate against bupivacaine anesthesia induced
toxicity involves modulation of PI3/Akt/PTEN signalling in N2a and
SH-SY5Y cells. Int J Clin Exp Med. 8:15065–15075. 2015.
|
|
30
|
Shankar S, Marsh L and Srivastava RK: EGCG
inhibits growth of human pancreatic tumors orthotopically implanted
in Balb C nude mice through modulation of FKHRL1/FOXO3a and
neuropilin. Mol Cell Biochem. 372:83–94. 2013. View Article : Google Scholar
|
|
31
|
Shen X, Zhang Y, Feng Y, Zhang L, Li J,
Xie YA and Luo X: Epigallocatechin-3-gallate inhibits cell growth,
induces apoptosis and causes S phase arrest in hepatocellular
carcinoma by suppressing the AKT pathway. Int J Oncol. 44:791–796.
2014.PubMed/NCBI
|
|
32
|
Li T, Yang Y, Li X, Xu C and Meng L: EGFR-
and AKT-mediated reduction in PTEN expression contributes to
tyrphostin resistance and is reversed by mTOR inhibition in
endometrial cancer cells. Mol Cell Biochem. 361:19–29. 2012.
View Article : Google Scholar
|
|
33
|
Van Aller GS, Carson JD, Tang W, Peng H,
Zhao L, Copeland RA, Tummino PJ and Luo L: Epigallocatechin gallate
(EGCG), a major component of green tea, is a dual
phosphoinositide-3-kinase/mTOR inhibitor. Biochem Biophys Res
Commun. 406:194–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shimizu M, Shirakami Y, Sakai H, Yasuda Y,
Kubota M, Adachi S, Tsurumi H, Hara Y and Moriwaki H:
(−)-Epigallocatechin gallate inhibits growth and activation of the
VEGF/VEGFR axis in human colorectal cancer cells. Chem Biol
Interact. 185:247–252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shirakami Y, Shimizu M, Adachi S, Sakai H,
Nakagawa T, Yasuda Y, Tsurumi H, Hara Y and Moriwaki H:
(−)-Epigallocatechin gallate suppresses the growth of human
hepatocellular carcinoma cells by inhibiting activation of the
vascular endothelial growth factor-vascular endothelial growth
factor receptor axis. Cancer Sci. 100:1957–1962. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ichimatsu D, Nomura M, Nakamura S,
Moritani S, Yokogawa K, Kobayashi S, Nishioka T and Miyamoto K:
Structure-activity relationship of flavonoids for inhibition of
epidermal growth factor-induced transformation of JB6 Cl 41 cells.
Mol Carcinog. 46:436–445. 2007. View
Article : Google Scholar : PubMed/NCBI
|
